Gilead (GILD) Officer Awarded 8,890 RSUs, Four-Year Vesting

Rhea-AI Filing Summary

Erin Burkhart, SVP, Controllership at Gilead Sciences (GILD), was granted 8,890 restricted stock units (RSUs) on 09/22/2025. Each RSU represents the contingent right to receive one share of common stock. The RSUs follow a four-year vesting schedule: 25% vests on the first anniversary of the grant date, with the remainder vesting at 6.25% each quarter thereafter until fully vested. Following the reported grant, Ms. Burkhart beneficially owns 8,890 shares subject to vesting, held directly. The Form 4 was filed by one reporting person and signed under power of attorney on 09/23/2025.

Positive

• Time-based RSU grant aligns the officer with shareholder interests through deferred equity compensation
• Clear vesting schedule (25% after one year, then 6.25% quarterly) supports retention over four years
• Direct beneficial ownership of 8,890 RSUs is fully disclosed on Form 4

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine executive equity grant aligning an officer with shareholder interests via time-based vesting.

The filing documents a time-based equity award to an officer rather than an immediate cash payment or sale. A grant of 8,890 RSUs to the SVP of Controllership is consistent with standard retention and alignment practices, using a four-year vesting schedule with an initial 25% cliff followed by quarterly vesting. This structure incentivizes tenure and reporting continuity but contains no performance-based conditions disclosed in this filing. The disclosure is limited to grant mechanics and ownership; there is no information here about grant valuation, relative size versus total compensation, or board approval details.

Compensation & Equity Specialist

TL;DR: Time‑based RSU grant appears routine; vesting cadence (25% then 6.25% quarterly) is standard for multi-year retention.

The award of 8,890 RSUs gives the officer a contingent right to the same number of common shares upon vesting. The explicit vesting schedule signals retention intent and gradual equity dilution as units vest. The Form 4 confirms direct beneficial ownership of the RSUs post-grant. Missing from the filing are the grant date fair value, any performance criteria, and comparison to peer grants, so assessment of materiality relative to total compensation cannot be made from this document alone.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burkhart Erin

(Last) (First) (Middle)

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Controllership

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	09/22/2025		A		8,890		(2)	(2)	Common Stock	8,890	(1)	8,890	D

Explanation of Responses:

1. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

2. The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.

Remarks:

	/s/ Edward S. Son by Power of Attorney for Erin E. Burkhart	09/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Erin Burkhart receive according to the Form 4 for GILD?

Ms. Burkhart was granted 8,890 restricted stock units (RSUs) on 09/22/2025, each representing the right to one share of Gilead common stock upon vesting.

What is the vesting schedule for the RSUs reported on GILD Form 4?

The RSUs vest over four years: 25% vests on the first anniversary of the grant date, with the balance vesting at 6.25% quarterly thereafter until fully vested.

How many shares does Erin Burkhart beneficially own following the reported transaction?

Following the grant, Ms. Burkhart beneficially owns 8,890 RSUs subject to vesting, held directly.

Was the Form 4 filed jointly or by a single reporting person for GILD?

The filing indicates it was filed by one reporting person and signed by power of attorney on 09/23/2025.

Does the Form 4 disclose any performance conditions for the RSUs?

No. The filing states the RSUs are time‑based with a four‑year vesting schedule and does not disclose any performance conditions.